Invitae Type VI Collagenopathy Panel


Test description

The Invitae Type VI Collagenopathy Panel analyzes up to four genes associated with type VI collagenopathies, which represent a variable spectrum of phenotypes, including Bethlem myopathy 1 (BTHLM1) and Ullrich congenital muscular dystrophy 1 (UCMD1), that are generally characterized by muscle weakness and contractures. These genes were curated based on current available evidence to provide a comprehensive test for the genetic causes of type VI collagenopathies.

Given that type VI collagenopathies are a heterogeneous group of disorders, identification of the underlying genetic cause can help predict outcome and inform recurrence risk.

Order test

Primary panel (3 genes)


Add-on preliminary-evidence gene (1 gene)

Preliminary-evidence genes currently have early evidence of a clinical association with the specific disease covered by this test. Some clinicians may wish to include a gene which does not currently have a definitive clinical association, but which may prove to be clinically significant in the future. This gene can be added at no additional charge. Visit our Preliminary-evidence genes page to learn more.


Alternative tests to consider

For a broader analysis of genes associated with myopathy, clinicians may consider the Invitae Congenital Myopathy Panel, or the Invitae Comprehensive Myopathy Panel. For a broader analysis of genes associated with muscular dystrophy, clinicians may consider either the Congenital Muscular Dystrophy Panel or the Comprehensive Muscular Dystrophy Panel. These broader panels can be ordered at no additional charge.

For a broader analysis of the genetics of hereditary neuromuscular disorders (muscular dystrophies, myopathies, and congenital myasthenic syndrome):

Type VI collagenopathies represent a variable spectrum of disorders that are characterized by muscle weakness and contractures. They range from the severe Ullrich congenital muscular dystrophy 1 (UCMD1) to the milder Bethlem myopathy 1 (BTHLM1). Intermediate disease presentations may also be observed. UCMD1 typically presents in the neonatal period with congenital muscle weakness, hypotonia, contractures, hip dislocation, and significant hyperlaxity of distal joints. Affected individuals have delayed motor development, progressive muscle weakness, and generalized muscle atrophy. BTHLM1 has variable age of onset, ranging from the prenatal period to adulthood, with onset of symptoms in childhood or early adulthood being most common. Clinical features of BTHLM1 include slowly progressive proximal muscle weakness and variable joint contractures. Ankles, elbows, and long finger flexors are the most commonly affected joints. Type VI collagenopathies can be associated with skin findings, including hypertrophic and keloid scarring. Intelligence is typically normal in affected individuals.

This test covers three genes associated with type VI collagenopathies, including COL6A2, which causes an estimated 44% of cases; COL6A1, which accounts for 38% of cases; and COL6A3, which accounts for the remaining 18% of cases.

Type VI collagenopathies can be inherited in an autosomal dominant or autosomal recessive manner. BTHLM1 is typically an autosomal dominant condition while UCMD1 is typically an autosomal recessive condition.

Individuals who carry a dominant pathogenic variant or two recessive pathogenic variants for a type VI collagenopathy are symptomatic. However, type VI collagenopathies are variable disorders, and some affected individuals may appear asymptomatic unless a careful clinical evaluation is performed.

The prevalence of BTHLM1 is approximately 1 in 100,000 and the prevalence of UCMD1 is approximately 1 in 1,000,000. Both conditions have been observed in a number of different ethnicities.

The clinical presentation of type VI collagenopathies can be variable. Genetic testing may confirm a suspected diagnosis or rule out disorders with similar symptoms. A genetic diagnosis may also help predict disease progression or inform recurrence risk.

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence, and select noncoding variants. Our assay provides a Q30 quality-adjusted mean coverage depth of 350x (50x minimum, or supplemented with additional analysis). Variants classified as pathogenic or likely pathogenic are confirmed with orthogonal methods, except individual variants that have high quality scores and previously validated in at least ten unrelated samples.

Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
COL12A1 NM_004370.5
COL6A1 NM_001848.2
COL6A2 NM_001849.3
COL6A3 NM_004369.3